Skip to main content
CHRS logo
CHRS
(NASDAQ)
Coherus Oncology, Inc.
$1.73-- (--)
Loading... - Market loading

Coherus Oncology (CHRS) Income Statement

Revenue, expenses, profit margins, and earnings with annual and quarterly data.

Coherus Oncology Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Coherus Oncology, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue42.1726.39257.24211.04326.55475.82356.071.561.56
Cost of Revenue17.748.73158.9970.0857.5937.6717.083.24160.53
Gross Profit24.4317.6698.25140.96268.96438.16338.99-1.68-158.98
Operating Expenses
Research & Development108.8991.83109.44199.36363.11142.7694.19110.24162.39
Selling, General & Administrative100.60125.48192.02198.48169.71139.08137.0494.1871.30
Operating Expenses203.97217.32291.45397.84532.82281.84231.23204.42233.69
Operating Income-179.53-199.65-193.20-256.88-263.86156.32107.77-204.42-232.14
Other Income/Expense
Interest Income0.004.502.801.900.000.600.000.000.00
Interest Expense9.0010.73-40.5432.4722.96-21.1717.609.689.55
Other Income/Expense-3.59-5.012.67-2.40-0.28-0.05-14.99-4.99-6.15
Income
Income Before Tax-183.12-215.39-238.27-291.75-287.10135.7192.78-209.41-238.29
Income Tax Expense0.000.00-0.380.000.003.462.940.000.00
Net Income-170.2928.51-237.89-291.75-287.10132.2489.83-209.34-238.17
Net Income - Continuous Operations-170.29-215.39-237.89-291.75-287.10132.2489.83-209.34-238.17
Net Income - Discontinued Operations351.15243.900.000.000.000.000.000.000.00
EBITDA-175.61-199.38-199.41-255.58-260.69159.21111.03-204.42-225.34
EBIT-181.13-204.66-203.20-259.28-264.14156.320.000.000.00
Depreciation & Amortization3.925.283.793.703.452.893.263.243.40
Earnings Per Share
Basic EPS-1.00--3.00-4.00-4.002.001.00-3.00-4.00
Diluted EPS-1.00--3.00-4.00-4.002.001.00-3.00-4.00
Basic Shares Outstanding120.37114.5594.1677.6375.4571.4169.6865.0153.13
Diluted Shares Outstanding120.37114.8394.1677.6375.4583.4973.1965.0353.13

Frequently Asked Questions About Coherus Oncology Financial Statements

What is an income statement?

An income statement shows a company's revenues, expenses, and net income over a specific period. It reveals profitability by starting with revenue and subtracting costs to arrive at net income — the "bottom line" that shows how much the company earned.

What is CHRS's revenue trend?

Review Coherus Oncology's quarterly and annual revenue figures in the income statement table above to identify growth trends, seasonal patterns, and year-over-year changes.

What is gross margin?

Gross margin is revenue minus cost of goods sold, expressed as a percentage. It shows how efficiently a company produces its goods or services. Higher gross margins indicate stronger pricing power and lower production costs.

What is operating income?

Operating income (EBIT) is revenue minus operating expenses, excluding interest and taxes. It measures a company's core business profitability before financing costs and tax effects, making it useful for comparing companies with different capital structures.

What is earnings per share (EPS)?

EPS divides net income by outstanding shares, showing the profit attributable to each share. Diluted EPS includes potential shares from stock options and convertible securities, providing a more conservative measure of per-share earnings.